HAROLD C. NEU, M.D.
Although readers of this journal undoubtedly know that the resistance of gram-negative bacteria to antibiotics is as much a problem today as staphylococcal resistance was in 1958, they are probably confused by the current plethora of cephalosporin-cefamycin agents. Have any of these new agents brought major improvements in antibacterial activity or pharmacokinetic properties? By the time this editorial is published, two new agents, cefamandole and cefoxitin, may be approved for use in the United States; these agents already are being used in Europe, as is another compound, cefuroxime, recently reviewed in a number of conference papers (1).
It is unlikely
NEU HC. Another Cephalosporin!. Ann Intern Med. ;89:719–720. doi: 10.7326/0003-4819-89-5-719
Download citation file:
Published: Ann Intern Med. 1978;89(5_Part_1):719-720.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use